FindTrial
Sign In

Distribution and drug resistance analysis of pathogenic bacteria in abdominal infection after liver resection, transarterial chemoembolization(TACE) and liver transplantation of the patients with primary liver cancer

Distribution and drug resistance analysis of pathogenic bacteria in abdominal infection after liver resection, transarterial chemoembolization(TACE) and liver transplantation of the patients with primary liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089764
Enrollment
Unknown
Registered
2024-09-14
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer

Interventions

Patients with abdominal infection after liver resection:None
Patients with abdominal infection after transarterial chemoembolization:None
Patients with abdominal infection after liver transplantation:None

Sponsors

Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: ?Patients are compatible with the diagnostic criteria of primary liver cancer; ?Patients were performed liver resection, transarterial chemoembolization(TACE) or liver transplantation; ?Patients with abdominal infection after surgery are compatible with the diagnostic criteria.

Exclusion criteria

Exclusion criteria: ?Patients with preoperative infection; ?Patients with incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Pathogenic bacteria;Drug resistance;—

Countries

China

Contacts

Public ContactCai Mengshan

Sun Yat-sen Memorial Hospital of Sun Yat-sen University

caimsh3@mail.sysu.edu.cn+86 159 1870 9395

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026